Table 1:

Baseline Patient Demographic and Clinical Characteristics

	Nivolumab dose de-escalation cohort (N=13)	Nivolumab Solid Tumor Expansion (N=23)	Overall (N=36)
Sex
Male	12 (92.3%)	21 (91.3%)	33 (91.7%)
Female	1 (7.7%)	2 (8.7%)	3 (8.3%)
Age
Median [Q1-Q3]	56.8 [53.7–59.4]	51.6 [40.6–58.9]	54.6 [47.5–59.3]
Race and Ethnicity
American Indian or Alaska Native	1 (7.7%)	0 (0%)	1 (2.8%)
Hispanic White	0 (0%)	3 (13.0%)	3 (8.3%)
Non-Hispanic Black	4 (30.8%)	6 (26.1%)	10 (27.8%)
Non-Hispanic White	8 (61.5%)	13 (56.5%)	21 (58.3%)
Other/Unknown	0 (0%)	1 (4.3%)	1 (2.8%)
Baseline CD4 count
>=200	5 (38.5%)	23 (100%)	28 (77.8%)
100–199	8 (61.5%)	0 (0%)	8 (22.2%)
Prior treatments received
0	0 (0%)	1 (4.3%)	1 (2.8%)
1	13 (100%)	20 (87.0%)	33 (91.7%)
2	0 (0%)	2 (8.7%)	2 (5.6%)
ECOG performance status
0	4 (30.8%)	11 (47.8%)	15 (41.7%)
1	9 (69.2%)	12 (52.2%)	21 (58.3%)
Tumor histology
Anal cancer	4 (30.8%)	0 (0%)	4 (11.1%)
Head & neck squamous cell carcinoma	2 (15.4%)	0 (0%)	2 (5.6%)
Kaposi’s Sarcoma	0 (0%)	15 (65.2%)	15 (41.7%)
Liver cancer	0 (0%)	1 (4.3%)	1 (2.8%)
Non-small cell lung cancer	1 (7.7%)	1 (4.3%)	2 (5.6%)
Others*	6 (46.2%)	6 (26.1%)	12 (33.3%)

^*Pancreatic cancer, skin squamous cell cancer, breast cancer, gallbladder cancer, follicular dendritic sarcoma, small cell lung cancer, colon cancer, squamous cell cancer of unknown primary, liposarcoma, and ovarian cancer